A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium. BTCRC-LUN17-127
Phase of Trial: Phase I/II
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Plinabulin (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 23 Oct 2018 According to a BeyondSpring Pharmaceuticals media release, top-line data form this trial is expected in 2H 2019.
- 04 Oct 2018 According to a BeyondSpring Pharmaceuticals media release, the first patient has received treatment in this trial on Sept. 11, 2018.
- 06 Sep 2018 Planned End Date changed from 1 Jul 2022 to 1 Sep 2022.